SCHEMBL7436725

SCHEMBL7436725

CCc1c[nH]c(=O)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036571 0.81
SCHEMBL7371567 0.76 GPR84 (0.58)
SCHEMBL20822090 0.75
SCHEMBL11174806 0.75 ATAD2 (0.40)
SCHEMBL20734513 0.74 GPR84 (0.61)
SCHEMBL20734517 0.74 GPR84 (0.61)
SCHEMBL161148 0.73 ATAD2 (0.54)
Hydrochloric Acid SCHEMBL30716696 0.73 DPYD (0.38)
SCHEMBL3662908 0.71
SCHEMBL5071203 0.68 GPR84 (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 WO disclosed
US-20230063116-A1 VEGF MINI-TRAPS AND METHOD OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-03-02 US disclosed
US-10807952-B2 Compounds for treatment of immune inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2020-10-20 US disclosed
US-20200262818-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2020-08-20 US disclosed
US-10428095-B2 Compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-10-01 US disclosed
US-10385097-B2 Ether compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-08-20 US disclosed
US-10370394-B2 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-08-06 US disclosed
US-10287301-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-05-14 US disclosed
US-20190031692-A1 COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2019-01-31 US disclosed
US-20180201580-A1 COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2018-07-19 US disclosed
EP-0059948-B1 NOVEL AROYLIMIDAZOLONES MERRELL DOW PHARMACEUTICALS INC. (US) 1985-11-13 EP disclosed
US-4552880-A Aroylimidazolones MERRELL DOW PHARMACEUTICALS INC. (US) 1985-11-12 US disclosed
EP-0118790-A1 Novel aroylimidazolones MERRELL DOW PHARMACEUTICALS INC. (US) 1984-09-19 EP disclosed
US-4447619-A CARDIOTONIC AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1984-05-08 US disclosed
US-4405628-A 4-Pyridylimidazolones and method of use MERRELL DOW PHARMACEUTICALS INC. (US) 1983-09-20 US disclosed
US-4405635-A HYPOTENSIVE, CARDIOTONIC, BRONCHODILATOR, ANTICOAGULANT, AND MUSCLE RELAXANT AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1983-09-20 US disclosed
EP-0079049-A2 Novel substituted alkanoylimidazol-2-one derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1983-05-18 EP disclosed
US-4367236-A CARDIOTONIC AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1983-01-04 US disclosed
EP-0059948-A1 Novel aroylimidazolones MERRELL DOW PHARMACEUTICALS INC. (US) 1982-09-15 EP disclosed
EP-0058435-A2 Novel 4-aroylimidazol-2-ones MERRELL DOW PHARMACEUTICALS INC. (US) 1982-08-25 EP disclosed